Go to Content

Red Arrow Therapeutics, K.K.
Development of pH-sensitive polymers as an inovative platform for protein delivery

As of January, 2025

City Year of Establishment Founder
Tokyo 2021 Takuya Miyazaki
Horacio Cabral
Rika Tajima
Partner VC Latest round of Fundraising Valuation
University of Tokyo Edge Capital Partners Seed Extension -

Program name

Deep-Tech Startups Support Program

Research theme

Development of pH-sensitive polymers as an inovative platform for protein delivery

Business Plan

We are developing pH-sensitive polymers as protein delivery systems. Our polymers can stably encapsulate therapeutic proteins at physiological pH while they can release active proteins at pathological pH. Since we have obtained early in vivo PoC, we are working on R&D activities to synthesize building blocks including polymers, proteins and their conjugates. Thus, by showing both therapeutic data and manufacturing data to pharmaceuticals as our potential customers, we are aiming to collaborate with them to translate our technology into business practice.

Research Outline

Since our systems are comprising polymers, proteins and their conjugates, we would like to conduct R&D activities to synthesize all these building blocks as follows:

  • [1] Development of synthesis method for polymers aiming to larger-scale manufacturing
  • [2] Development of synthesis method for proteins aiming to larger-scale manufacturing
  • [3] Development of synthesis method for conjugates aiming to larger-scale manufacturing
Phase Business Area/Field Research Period Research Grant Amount
STS Healthcare 2024~2025FY JPY 356 million

International collaborative technology demonstration

Countries/Regions Collaborative activity outline
Europe
  • - Relationship development with potential local partner
By partnering with manufactures, we are going to develop synthesis method to construct our novel polymers and conjugates.

Last Updated : May 22, 2025